Takeda Pharmaceutical Company Ltd
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer
Active, not recruiting
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Takeda
- Target Recruit Count
- 757
- Registration Number
- NCT02394834
Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC
Phase 3
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Takeda
- Target Recruit Count
- 823
- Registration Number
- NCT02394795
Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate
Phase 2
Terminated
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2019-02-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 7
- Registration Number
- NCT02393378
Proof of Mechanism Study of MLN1202 on Atherosclerotic Inflammation in Participants With Stable Atherosclerotic Cardiovascular Disease
Phase 2
Withdrawn
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Drug: MLN1202Drug: Placebo
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2015-12-10
- Lead Sponsor
- Takeda
- Registration Number
- NCT02388971
A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 493
- Registration Number
- NCT02389816
Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis
Phase 3
Completed
- Conditions
- Erosive Esophagitis
- Interventions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2019-06-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 481
- Registration Number
- NCT02388724
- Locations
- 🇰🇷
Kangbuk Samsung Hospital, Seoul, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
🇰🇷The Catholic University of Korea, Seoul St. Marys Hospital, Seoul, Korea, Republic of
Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis
Phase 3
Completed
- Conditions
- Erosive Esophagitis
- Interventions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2020-02-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 703
- Registration Number
- NCT02388737
- Locations
- 🇲🇾
University Malaya Medical Centre, Kuala Lumpur, Malaysia
🇨🇳Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
🇨🇳Taipei Medical University Hospital, Taipei City, Taiwan
Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy Participants
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Takeda
- Target Recruit Count
- 40
- Registration Number
- NCT02389881
Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Maalox Advance Regular Strength liquid
- First Posted Date
- 2015-03-09
- Last Posted Date
- 2016-04-29
- Lead Sponsor
- Takeda
- Target Recruit Count
- 36
- Registration Number
- NCT02382640
Effects of TAK-448 in Middle-aged and Older Men With Low Testosterone
- First Posted Date
- 2015-03-06
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Takeda
- Target Recruit Count
- 17
- Registration Number
- NCT02381288
© Copyright 2025. All Rights Reserved by MedPath